CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 21:00:02 24/07/2026 BST			5-day change	1st Jan Change
226.58 ^USD	-1.18%		+0.99%	+13.59%

07-20	Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix…
07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT

All News

Mentions Relevance

07-15	Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call	BU
07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
07-13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
07-13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
07-13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
07-13	Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating	MT
07-13	Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	BU
07-09	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-07	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-03	Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?	PR
07-01	Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing	MT
07-01	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT
06-18	Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise	BU
06-18	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT
06-17	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade	MT
06-17	Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185	MT
06-05	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says	MT
06-03	Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM
06-02	Charles River Laboratories International, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10:00 AM
06-01	Charles River Laboratories to Present at William Blair and Jefferies Conferences	BU
05-13	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
05-13	Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions	RE
05-13	Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions	BU
05-11	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
05-11	Charles River Laboratories International, Inc. Announces Board Elections	CI